Wellcome Trust | Advancing target validation for novel mental health drug discovery
Event details
| Date | 15.04.2025 |
| Category | Call for proposal |
Aim: Wellcome's Mental Health Award - Advancing Target Validation for Novel Mental Health Drug Discovery call wishes to fund validation activities for novel targets with a clear therapeutic concept and strong biological rationale related to early intervention in anxiety, depression and/or psychosis. Funded proposals will generate data supporting the target's therapeutic potential in the development of new and improved pharmacological treatments. This call has been designed in collaboration with the Psychiatry Consortium to help enable early and robust target validation research.
Successful projects will generate data demonstrating the target's potential to lead to a clinical benefit, including toxicity risk considerations, and will develop the potential for a drug discovery campaign. Early elimination of non-viable targets is also important to better inform future research hypotheses and experimental designs. Wellcome defines a 'target' as a biochemical entity in the body that a drug can bind to, including, but not limited to, receptors, proteins, enzymes, biomolecules (eg DNA, RNA, peptides) and gut microbiome.
Funding: up to £700,000 (0% overheads)
Duration: up to 2 years
Eligibility: Application is open to teams of researchers based anywhere in the world (apart from mainland China). The team must be from disciplines relevant to drug discovery and mental health science, including, but not limited to, genomics, computational psychiatry, molecular biology in psychiatry, medical chemistry, neuropharmacology, in-vitro/vivo/silico pharmacology and drug discovery.
Team, Lead applicant, Co-applicant, and Collaborator criteria can found be here.
How to Apply: Applications should be completed through Wellcome’s online portal using the preliminary application form.
Deadline: 15 April 2025
Further information
Successful projects will generate data demonstrating the target's potential to lead to a clinical benefit, including toxicity risk considerations, and will develop the potential for a drug discovery campaign. Early elimination of non-viable targets is also important to better inform future research hypotheses and experimental designs. Wellcome defines a 'target' as a biochemical entity in the body that a drug can bind to, including, but not limited to, receptors, proteins, enzymes, biomolecules (eg DNA, RNA, peptides) and gut microbiome.
Funding: up to £700,000 (0% overheads)
Duration: up to 2 years
Eligibility: Application is open to teams of researchers based anywhere in the world (apart from mainland China). The team must be from disciplines relevant to drug discovery and mental health science, including, but not limited to, genomics, computational psychiatry, molecular biology in psychiatry, medical chemistry, neuropharmacology, in-vitro/vivo/silico pharmacology and drug discovery.
Team, Lead applicant, Co-applicant, and Collaborator criteria can found be here.
How to Apply: Applications should be completed through Wellcome’s online portal using the preliminary application form.
Deadline: 15 April 2025
Further information
- More information about the program is available here
- Webinar recording available here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free
Contact
- research@epfl.ch